Stockscreener 앱 받기
9.15
3.07%
-0.29
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ViatrisVTRS - Markets Insider
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible - GlobeNewswire
Viatris Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viatris Inc. (VTRS) - ACCESS Newswire
Viatris Inc. Announcement: If You Have Suffered Losses in - GlobeNewswire
Did Viatris Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateVTRS - ACCESS Newswire
VTRS Investigation: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action InvestigationVTRS - PR Newswire
Is Viatris Inc. (VTRS) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - StreetInsider.com
Opus, Viatris Unit Sue Sandoz to Block Copy of Ryzumvi Eye Drug - Bloomberg Law
Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are ... - The Bakersfield Californian
Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Viatris Inc. Under Investor Scrutiny: Levi & Korsinsky Launches Securities Investigation - Apna Kal
Viatris Stock Plummets Over 15% Amid Earnings Miss and FDA Warning – Investors Encouraged to Take Action - Apna Kal
Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation – VTRS - Bluefield Daily Telegraph
Viatris Inc (VTRS) Volatility Hits 3.27% – Here Is What You Should Do - Stocks Register
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Shareholders to Reach Out - Markets Insider
Investors who Lost Money on Viatris Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationVTRS - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Viatris Inc. (VTRS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - PR Newswire
Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds - Investing.com
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds By Investing.com - Investing.com UK
Viatris Inc. (VTRS) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Viatris at Barclays Conference: Strategic Moves Amid Challenges - Investing.com
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc.VTRS - PR Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Viatris Inc. (VTRS) Regarding Possible Securities Fraud Violations - ACCESS Newswire
ATTENTION Viatris Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Why Viatris Inc. (VTRS) Is Plunging So Far In 2025 - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Viatris Inc. (VTRS) And Encourages Investors to Connect - Markets Insider
Viatris price target lowered to $13 from $15 at Jefferies - MSN
LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Jefferies cuts Viatris stock price target to $13, maintains Buy - Investing.com
Jefferies Adjusts Viatris Price Target to $13 From $15, Maintains Buy Rating -March 07, 2025 at 12:10 pm EST - Marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Viatris Inc. (VTRS) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Viatris Inc. (VTRS) and Encourages Investors to Learn More About the Investigation - Markets Insider
ATTENTION VTRS SHAREHOLDERS: Investors who lost money on Viatris Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Viatris to Present at the Barclays 27th Annual Global Healthcare Conference - PR Newswire
Viatris stock target cut to $10 by Piper Sandler, maintains neutral - Investing.com India
Forecasting The Future: 4 Analyst Projections For Viatris - Benzinga
Viatris price target lowered to $10 from $14 at Piper Sandler - TipRanks
Viatris Inc. Being Investigated on Behalf of Viatris Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Piper Sandler Adjusts Price Target on Viatris to $10 From $14, Maintains Neutral Rating - Marketscreener.com
Analyst recommendations: Applovin, Palantir, T-Mobile US, Constellation Brands, Viatris… - Marketscreener.com
Wall Street Wary as Viatris (VTRS) Dives into Generic Weight Loss Drug Market - Markets Insider
Viatris outlines $450M-$550M product revenue target for 2025 while addressing Indore impact - MSN
1.68%
1.15%
자본화:
|
볼륨(24시간):